Cargando…

2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis

BACKGROUND: Augmented concern for methicillin-resistant Staphylococcus aureus (SA) infections in intensive care units (ICU) has led to increased empiric vancomycin use (EVU) in patients with suspected pneumonia, bacteremia, and/or sepsis. At Tufts Medical Center, vancomycin is prescribed at clinicia...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Christina Y, Walsh, Ashton, Campion, Maureen, Foong, Kap Sum, Doron, Shira, Vazquez, Gabriela Andujar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678860/
http://dx.doi.org/10.1093/ofid/ofad500.1862
_version_ 1785150459323875328
author Xie, Christina Y
Walsh, Ashton
Campion, Maureen
Foong, Kap Sum
Doron, Shira
Vazquez, Gabriela Andujar
author_facet Xie, Christina Y
Walsh, Ashton
Campion, Maureen
Foong, Kap Sum
Doron, Shira
Vazquez, Gabriela Andujar
author_sort Xie, Christina Y
collection PubMed
description BACKGROUND: Augmented concern for methicillin-resistant Staphylococcus aureus (SA) infections in intensive care units (ICU) has led to increased empiric vancomycin use (EVU) in patients with suspected pneumonia, bacteremia, and/or sepsis. At Tufts Medical Center, vancomycin is prescribed at clinician discretion without restrictions. We aimed to evaluate the impact of cultures on EVU and identify predictors associated with prolonged EVU among ICU patients with cultures negative (CN) for SA. METHODS: A retrospective study from April 2022 to January 2023 of ICU adult patients with EVU for suspected pneumonia, bacteremia, or sepsis was conducted. ICU service, length of stay (LOS), duration of EVU, blood & respiratory cultures, mechanical ventilation (MV), central line presence, and vasopressor use were collected. Prolonged EVU was defined as vancomycin use for more than 2 days despite CN for SA. The primary outcome was the rate of prolonged EVU discontinuation. Linear regression included demographics, ICU service, LOS, indication, Charlson Co-morbidity Index, lactate, MV, and 0.5 mg/dL serum creatinine change. Logistic regression included the same variables plus age, positive respiratory cultures and MV interaction. RESULTS: A total of 165 ICU patients had EVU. Of these, 132 (80%) had cultures collected before EVU vs. 33 (20%) that did not. Blood cultures were collected in 117 (88.6%); 66 (49.6%) had respiratory cultures; 51 (38.6%) had both collected. Median vancomycin duration was 2 days (1-3). Prolonged EVU was observed in 47 (46.1%) patients, while 55 (53.9%) had EVU discontinued within 2 days with CN for SA. On average Cardiac Surgery (CS) spent 2 days longer on vancomycin compared to Surgical (p=0.037) and Pulmonary (p=0.01) patients. MV among ICU patients was less likely to be associated with vancomycin discontinuation within 2 days with CN for SA (aOR [adjusted odd ratio] 0.12, 95% CI 0.03, 0.50; p=0.003). CONCLUSION: EVU discontinuation was more likely within 2 days in ICU patients with CN for SA, but less likely for MV or CS patients. In a substantial proportion of patients, cultures were not collected. Our findings highlight the importance of diagnostic testing in ICU settings to help reduce EVU. DISCLOSURES: Maureen Campion, PharmD, Shinoigi: Speaker
format Online
Article
Text
id pubmed-10678860
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106788602023-11-27 2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis Xie, Christina Y Walsh, Ashton Campion, Maureen Foong, Kap Sum Doron, Shira Vazquez, Gabriela Andujar Open Forum Infect Dis Abstract BACKGROUND: Augmented concern for methicillin-resistant Staphylococcus aureus (SA) infections in intensive care units (ICU) has led to increased empiric vancomycin use (EVU) in patients with suspected pneumonia, bacteremia, and/or sepsis. At Tufts Medical Center, vancomycin is prescribed at clinician discretion without restrictions. We aimed to evaluate the impact of cultures on EVU and identify predictors associated with prolonged EVU among ICU patients with cultures negative (CN) for SA. METHODS: A retrospective study from April 2022 to January 2023 of ICU adult patients with EVU for suspected pneumonia, bacteremia, or sepsis was conducted. ICU service, length of stay (LOS), duration of EVU, blood & respiratory cultures, mechanical ventilation (MV), central line presence, and vasopressor use were collected. Prolonged EVU was defined as vancomycin use for more than 2 days despite CN for SA. The primary outcome was the rate of prolonged EVU discontinuation. Linear regression included demographics, ICU service, LOS, indication, Charlson Co-morbidity Index, lactate, MV, and 0.5 mg/dL serum creatinine change. Logistic regression included the same variables plus age, positive respiratory cultures and MV interaction. RESULTS: A total of 165 ICU patients had EVU. Of these, 132 (80%) had cultures collected before EVU vs. 33 (20%) that did not. Blood cultures were collected in 117 (88.6%); 66 (49.6%) had respiratory cultures; 51 (38.6%) had both collected. Median vancomycin duration was 2 days (1-3). Prolonged EVU was observed in 47 (46.1%) patients, while 55 (53.9%) had EVU discontinued within 2 days with CN for SA. On average Cardiac Surgery (CS) spent 2 days longer on vancomycin compared to Surgical (p=0.037) and Pulmonary (p=0.01) patients. MV among ICU patients was less likely to be associated with vancomycin discontinuation within 2 days with CN for SA (aOR [adjusted odd ratio] 0.12, 95% CI 0.03, 0.50; p=0.003). CONCLUSION: EVU discontinuation was more likely within 2 days in ICU patients with CN for SA, but less likely for MV or CS patients. In a substantial proportion of patients, cultures were not collected. Our findings highlight the importance of diagnostic testing in ICU settings to help reduce EVU. DISCLOSURES: Maureen Campion, PharmD, Shinoigi: Speaker Oxford University Press 2023-11-27 /pmc/articles/PMC10678860/ http://dx.doi.org/10.1093/ofid/ofad500.1862 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Xie, Christina Y
Walsh, Ashton
Campion, Maureen
Foong, Kap Sum
Doron, Shira
Vazquez, Gabriela Andujar
2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis
title 2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis
title_full 2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis
title_fullStr 2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis
title_full_unstemmed 2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis
title_short 2240. Breaking Dogmas: A Single Center Evaluation of Empiric Vancomycin Use Among Intensive Care Unit Patients with Suspected Pneumonia, Bacteremia or Sepsis
title_sort 2240. breaking dogmas: a single center evaluation of empiric vancomycin use among intensive care unit patients with suspected pneumonia, bacteremia or sepsis
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678860/
http://dx.doi.org/10.1093/ofid/ofad500.1862
work_keys_str_mv AT xiechristinay 2240breakingdogmasasinglecenterevaluationofempiricvancomycinuseamongintensivecareunitpatientswithsuspectedpneumoniabacteremiaorsepsis
AT walshashton 2240breakingdogmasasinglecenterevaluationofempiricvancomycinuseamongintensivecareunitpatientswithsuspectedpneumoniabacteremiaorsepsis
AT campionmaureen 2240breakingdogmasasinglecenterevaluationofempiricvancomycinuseamongintensivecareunitpatientswithsuspectedpneumoniabacteremiaorsepsis
AT foongkapsum 2240breakingdogmasasinglecenterevaluationofempiricvancomycinuseamongintensivecareunitpatientswithsuspectedpneumoniabacteremiaorsepsis
AT doronshira 2240breakingdogmasasinglecenterevaluationofempiricvancomycinuseamongintensivecareunitpatientswithsuspectedpneumoniabacteremiaorsepsis
AT vazquezgabrielaandujar 2240breakingdogmasasinglecenterevaluationofempiricvancomycinuseamongintensivecareunitpatientswithsuspectedpneumoniabacteremiaorsepsis